iRhythm Technologies (IRTC) 2024 Wells Fargo Healthcare Conference summary

Business performance and outlook

• Q3 volumes showed typical seasonal trends, with July strong, a softer early August, and a rebound in late August; full-year guidance remains on track, with Q3 expected to contribute about 25% of annual revenue.

• Primary care adoption is increasing, with new account onboarding strong and large customers now in primary care.

• International expansion is underway, with launches in four EU countries and Japan expected to receive regulatory approval and reimbursement in early 2025, positioning for significant growth.

• The company maintains confidence in achieving $1 billion in revenue by 2027, with unit volume growth around 20% and further acceleration expected from new product launches and international markets.

• Asymptomatic AF partnerships are expanding, with pilots growing in several states and broader commercial launches anticipated in 2025.

Technology and platform expansion

• A new license agreement with BioIntelliSense enables advanced pulse oximetry and multi-vital sign monitoring directly from the chest, expanding the platform beyond cardiac rhythm monitoring.

• The technology allows for cleaner signals, improved accuracy across skin pigmentation, and supports new use cases such as home sleep testing and heart failure management.

• The platform aims to address broader patient monitoring needs, including hypertension and post-hospital discharge, offering cost-saving opportunities for hospital systems.

• The company is focused on integrating multimodal sensing into a single platform, with strong IP protection in the pulse oximetry space.

Regulatory and compliance updates

• The company is addressing significant FDA Form 483 observations, prioritizing remediation across quality systems, documentation, and integration of CCTs into processes.

• The FDA now considers the IDTF/CCT part of the product, and the company has agreed to fully align its quality system accordingly.

• Remediation is expected within 12 months, with external consultants engaged and monthly updates provided to the FDA.

• The warning letter and Form 483s are being addressed in parallel, with five 510(k)s expected to be approved in September or October, followed by a closeout inspection likely in Q1.

• The company is committed to a culture of quality, making leadership changes and prioritizing regulatory compliance as its top focus.